Clean Science: Leading Specialty Chemicals with Growth Potential

Clean Science & Technology Ltd is a global leader in specialty chemicals manufacturing, with top positions in MEHQ, BHA, and AP—key performance chemicals. The company also produces pharmaceutical intermediates like Guaiacol and DCC, and FMCG chemicals such as Anisole and 4-MAP. Its remarkable strength lies in large manufacturing capacities across flagship products. MEHQ ranks number one globally in production, supported by its expansive chemical variants. The company runs 4 advanced manufacturing units, pilot plants, and well-equipped labs to maintain quality and innovation. Innovation is a key driver for

Science, with 16 accreditations and four research & development centers employing over 90 scientists. The company maintains a diverse technology portfolio covering hydroxylation, chlorination, oxidation, alkylation, Grignard Reaction, hydrogenation, and catalysis. Management expects multiple major product approvals globally by FY26, which can provide substantial business growth. Despite growth potential, financials showed a 7.34% year-on-year sales decline in Q2FY26 to ₹211 crore, and net profit dropped 4% to ₹65 crore. Currently, the stock trades at a price-to-earnings ratio of 33.6x, slightly above the industry median, reflecting valuation in line with peers. Domestic institutional investors increased their holdings significantly during Q2FY26, reflecting confidence in the company’s future. For shareholders, Clean Science is a valuable investment due to its leadership in specialty chemicals, strong manufacturing scale, ongoing innovation, and potential for global approval-driven growth. While recent financials were soft, its robust fundamentals and market position provide a positive outlook for long-term value.